A combination of two antibodies, the anti-programmed cell death ligand 1 (anti-PD-L1; atezolizumab) and anti-vascular endothelial growth factor (anti-VEGF; bevacizumab) antibodies, has proven to be the most effective FDA-approved first-line treatment for advanced non-resectable HCC with an overall response rate of 27% [12,14,15]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.